Table 1. Characteristics of the 25 Parenteral Cancer Therapies Included in the Analysis of Price Transparency.
| Variable | No. of drugs (%) |
|---|---|
| Initial FDA approval year | |
| 2013-2017 | 10 (40.0) |
| 2008-2012 | 6 (24.0) |
| Before 2008 | 9 (36.0) |
| Molecule type | |
| Small | 7 (28.0) |
| Biologic | 17 (68.0) |
| Other | 1 (4.0) |
| Generic or biosimilar agent approveda | |
| Yes | 9 (36.0) |
| No | 16 (64.0) |
| Orphan drug designationb | |
| Yes | 20 (80.0) |
| No | 5 (20.0) |
| Breakthrough designationb | |
| Yes | 11 (44.0) |
| No | 14 (56.0) |
| Oncologic disease areac | |
| Hematologic | 11 (44.0) |
| Pulmonary | 9 (36.0) |
| Breast | 7 (28.0) |
| Gastrointestinal | 7 (28.0) |
| Hepatobiliary | 6 (24.0) |
| Genitourinary | 5 (20.0) |
| Cutaneous | 4 (16.0) |
| Renal | 4 (16.0) |
| Head/neck | 3 (12.0) |
| Other | 3 (12.0) |
| Gynecologic | 2 (8.0) |
| 2019 Medicare Part B spending (millions), $ | |
| >500 | 7 (28.0) |
| 250-500 | 9 (36.0) |
| <250 | 9 (36.0) |
Abbreviation: FDA, Food and Drug Administration.
a
Approval status as of April 26, 2021.
b
Includes designations for both original and supplemental FDA-approved indications.
c
Non–mutually exclusive categorizations.